Intellia Therapeutics

7 active clinical studies registered on ClinicalTrials.gov, the most advanced in Phase 3. Next estimated primary completion: Jul 2027.

Clinical pipeline

Primary completion	Phase	Status	Condition and study
4 Apr 2024 passed	Phase 1/2?	Active, not recruiting	Hereditary Angioedema NTLA-2002 in Adults With Hereditary Angioedema (HAE) · NCT05120830
10 Feb 2026 passed	Phase 3?	Active, not recruiting	Hereditary Angioedema HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) · NCT06634420
Jul 2027	Phase 3?	Recruiting	Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease A Phase 3 Study of NTLA-2001 in ATTRv-PN · NCT06672237
Dec 2027	Phase 3?	Recruiting	Transthyretin Amyloidosis (ATTR) With Cardiomyopathy MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) · NCT06128629
14 Aug 2034	Phase 1/2?	Recruiting	Hemophilia B A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B · NCT06379789
Mar 2038	N/A	Enrolling by invitation	Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001 · NCT05697861
Apr 2040	N/A	Enrolling by invitation	Hereditary Angioedema Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002 · NCT06262399

Source: ClinicalTrials.gov, studies with the company as sponsor and an active status. Data fetched 7 October 2026.